Metabolic therapy for the treatment of ischemic heart disease: reality and expectations.

Metabolic therapy for the treatment of ischemic heart disease: reality and expectations. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

Metabolic therapy for the treatment of ischemic heart disease: reality and expectations. Abstract Text:

Wei Wang,Gary D Lopaschuk,Wei Wang,Gary D Lopaschuk,

Ischemic heart disease is a major cause of morbidity and mortality in the world. Most of the existing therapeutic strategies used to treat ischemic heart disease aim at either increasing the oxygen supply to the heart (thrombolysis, revascularization, angiotensin converting enzyme inhibition and antiplatelet therapy) or decreasing the oxygen demand of the heart (beta-blockers and nitrates). Despite the fact that a compromised energy supply to the heart muscle is central to the pathology of ischemic heart disease, therapeutic approaches that focus on altering cardiac energy metabolism have not seen major clinical use. Therapeutic strategies in which the efficiency of oxygen utilization by the heart is enhanced could theoretically benefit the ischemic heart, and could have an additive benefit to existing therapeutic strategies. The energy supply for the heart (in the form of ATP) is normally provided by the balanced metabolism of both fatty acids (major part) and carbohydrates (minor part) oxidation. During reperfusion, this balance is broken by the dramatic enhancement of fatty acid oxidation and attenuation of carbohydrate oxidation, which results in intracellular H(+) accumulation and Ca(2+) overload. This article reviews the alterations in cardiac energy metabolism that occur in the ischemic heart, and discusses the existing and proposed pharmacologic therapies to optimize the balance of fatty acids and carbohydrate oxidation for the treatment of ischemic heart diseases.

Metabolic therapy for the treatment of ischemic heart disease: reality and expectations. Publishing Authors By Initials

W Wang,GD Lopaschuk,W Wang,GD Lopaschuk,

For similar abstracts research abstracts see: abstracts research

PUBMED ID PMID:

MEDLINE DATE:

Metabolic therapy for the treatment of ischemic heart disease: reality and expectations. Journal Published:

PUBLICATION TYPE: Journal Article

Journal: Expert review of cardiovascular therapy

VOLUME: 5

Page Numbers: 1123-34

Journal Abbreviation:

ISSN: 1744-8344

DAY: 26

MONTH: Nov

YEAR: 2007

Metabolic therapy for the treatment of ischemic heart disease: reality and expectations. Information

Number of References:

LANGUAGE: eng

NlmUniqueID: 101182328

Metabolic therapy for the treatment of ischemic heart disease: reality and expectations. Keywords Mesh Terms:

KEYWORDS:

MESH TERMS:

Chemical & Substance for Abstract: Metabolic therapy for the treatment of ischemic heart disease: reality and expectations. Information

Substance Name:

Registry Number:

Grant and Affiliation Information for Metabolic therapy for the treatment of ischemic heart disease: reality and expectations.

AFFILIATION: University of Alberta, 423 Heritage Medical Research Center, Edmonton, Alberta T6G 2S2, Canada. wwang3@ualberta.ca

Country: England

AGENCY:

GRANT:

ACRONYM:

MEDLINETA: Expert Rev Cardiovasc Ther

REFSOURCE:

DATABASENAME:

ACCESSION NUMBER:

Number Hits: 0

Metabolic therapy for the treatment of ischemic heart disease: reality and expectations Related Publications

• Alpha-lipoic acid increases cardiac glucose oxidation independent of AMP-activated protein kinase in isolated working rat hearts.
• Alterations in myocardial fatty acid metabolism contribute to ischemic injury in the diabetic.
• Metabolic therapy for the treatment of ischemic heart disease: reality and expectations.
• Myosin regulatory light chain E22K mutation results in decreased cardiac intracellular calcium and force transients.
• The malonyl CoA axis as a potential target for treating ischaemic heart disease.